Principal Investigator

Regine Choe, Ph.D. University of Rochester work 601 Elmwood Ave Rochester NY 14642 office: MC 5-7233A p (585) 273-4374

Honors & News

  • October 29, 2015

    Choe and Benoit Awarded NSF Grant to Develop Safe, Noninvasive Imaging Methods to Monitor Bone Graft Healing

    BME Professors Regine Choe (Principal Investigator) and Danielle Benoit (Co-Investigator) have been awarded an NSF Grant for their collaborative research project entitled, Diffuse Optical and Correlation Tomography for Monitoring of Bone-Graft Headling. The overall goal of this proposal is to develop new and safe imaging methods that use red and infrared light to monitor and image the re-growth of blood vessels in healing bones. These methods are based on diffuse optical tomography (DOT) and diffuse correlation tomography (DCT) as scientific research tools to provide non-invasive, deep-tissue longitudinal monitoring of vascularization of engineered tissues. Techniques that non-invasively monitor and longitudinally assess the vascularization process could significantly accelerate the tissue-engineering field, which will lead to new methods for healing damaged tissues. By providing efficient ways to assess vascularization, this methodology will impact the speed of clinical translation of new tissue-engineering technologies, saving time and reducing development costs.

    The project will involve educational outreach to underrepresented high school student groups through interaction with the David T. Kearns Center for Leadership and Diversity in Arts, Sciences and Engineering at the University of Rochester, and an international collaboration with a biomedical optics group at the Institute of Photonic Sciences, Spain.

  • August 25, 2011

    Dr. Regine Choe Awarded NIH Grant to Pursue Development of Cost-Effective Modality to Monitor Ongoing Breast Cancer Therapy

    BME assistant professor, Dr. Regine Choe has received a three-year NIH Pathway to Independence Award ($700,000) to investigate an alternative method to positron emission tomography (PET) scans to assess the effectiveness of chemotherapy for breast cancer. Because PET scans are relatively expensive, and since the contrast agent, Flurodeoxyglucose (18F-FDG), contains radioactive compounds, frequent assessment of breast cancer tumors over the course of chemotherapy treatment makes PET scans a less than optimal choice.

    The Choe lab will be using a new fluorescent dye to investigate if it can be used as a surrogate marker for glucose metabolism. In addition, the lab will investigate whether simultaneous monitoring of glucose and oxygen metabolism accessible by diffuse optical methods (with and without injection) can enhance the assessment of treatment efficacy.

    We hope to find a less expensive, safer modality to measure metabolic changes in tumors induced by chemotherapy. The ultimate goal is to be able to determine if the chemotherapy is effective before the course of treatment is over, thus making it possible to change or discontiue the course of treatment if necessary, says Dr. Choe.

Recent Publications